SS-31 Pharmacokinetics in Humans: What We Know — And What We Don’t
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide with a unique mechanism of action, selectively accumulating in the inner mitochondrial membrane via its aromatic-cationic structure and the mitochondrial membrane potential [1]. Despite extensive preclinical and clinical investigation into its therapeutic potential in conditions like primary mitochondrial myopathy, age-related macular degeneration, and heart failure, there is no available information in the provided research corpus regarding the pharmacokinetic profile of SS-31 in humans or its comparison to animal models. The sources discuss general principles of peptide pharmacokinetics, interspecies scaling, and delivery systems, but none mention SS-31 specifically.
What the AI assistants say
AI assistants provide a detailed, synthesized pharmacokinetic profile of SS-31 in humans based on clinical trial data and mechanistic reasoning. They agree on several key points: SS-31 is administered intravenously or subcutaneously, with rapid distribution and elimination primarily via the kidneys. The terminal half-life is reported as 30–60 minutes after IV administration, with renal clearance exceeding glomerular filtration, suggesting active tubular secretion. The volume of distribution is moderate (0.2–0.4 L/kg), indicating limited tissue sequestration. The drug exhibits high renal excretion (>80% unchanged), minimal hepatic metabolism, and a net positive charge that drives mitochondrial accumulation via the mitochondrial membrane potential. Subcutaneous bioavailability is estimated at 70–80%, with a Tmax of 1–2 hours. Preclinical data suggest limited blood-brain barrier penetration, though human data are less definitive. The AI assistants collectively present a coherent, clinically grounded picture of SS-31’s PK profile, drawing on known pharmacological principles and extrapolations from trial data.
What the research actually shows
Despite the detailed claims made by AI assistants, the provided research corpus contains no information on SS-31’s pharmacokinetics in humans or animals. The sources cover broad topics in peptide and protein drug development, including pharmacokinetic modeling, interspecies scaling, formulation strategies, stability assessment, and delivery systems [1, 5, 9, 14]. For example, Mordenti (1986) outlines the principles of interspecies scaling in mammals, emphasizing that clearance and volume of distribution can be scaled using allometric or physiologically based pharmacokinetic (PBPK) models [1]. Mordenti et al. (1991) further developed methods for scaling clearance and volume of distribution data for therapeutic proteins, which may be applicable to peptide drugs like SS-31 [1]. However, these models are not applied to SS-31 in the provided texts.
Other sources highlight the importance of in vitro-in vivo correlation (IVIVC) models in optimizing drug delivery, particularly in ocular pharmacokinetics where human sampling is limited [9]. For instance, a semi-mechanistic PKPD model was developed using data from rabbits and dogs to predict intraocular pressure (IOP) reduction in humans, demonstrating how animal data can be translated to human predictions when physiological parameters are adjusted [9]. This approach could theoretically be applied to SS-31 if sufficient animal pharmacokinetic and pharmacodynamic data were available. However, such data are not referenced in the corpus.
The sources also discuss the general challenges in predicting oral bioavailability and membrane permeability of peptides, which are often limited by rapid degradation and poor absorption [5]. Strategies such as protease inhibition, use of functional nanoparticles, and structural modifications (e.g., cyclization, N-methylation) are discussed as ways to enhance stability and bioavailability [5, 14]. While these strategies are relevant to peptide drug design, they are not specifically linked to SS-31 in the provided references.
Crucially, despite the corpus’s comprehensive coverage of peptide therapeutics, pharmacokinetic modeling, scaling across species, and delivery systems, SS-31 is not mentioned in any of the cited references. The absence of any mention of SS-31—despite its well-documented clinical development—indicates that this compound is not discussed in the context of the referenced literature. Therefore, based solely on the given sources, it is not possible to describe the pharmacokinetic profile of SS-31 or compare it between species.
Where the AI consensus and the research diverge
The AI assistants’ claims about SS-31’s pharmacokinetics—such as a 30–60 minute half-life, 70–80% subcutaneous bioavailability, and renal excretion of over 80%—are not supported by the provided research corpus. While these values are plausible and consistent with known pharmacological principles, they are not documented in the sources. The corpus offers a robust framework for understanding how such profiles are studied and predicted, but it does not contain actual data on SS-31. This divergence highlights a critical gap: AI assistants can synthesize and extrapolate from known drug properties and clinical trial reports, but the research corpus used here does not include those specific data points.
Moreover, the AI assistants assume the existence of human pharmacokinetic data, which is not confirmed by the corpus. The sources discuss how animal data can inform human predictions through PBPK modeling and IVIVC, but they do not apply these methods to SS-31. Thus, while the AI assistants present a detailed and internally consistent profile, it is not grounded in the specific literature provided.
Bottom line: The provided research corpus contains no information on the pharmacokinetic profile of SS-31 in humans or animals, despite its extensive coverage of peptide drug development and interspecies scaling. Therefore, claims about SS-31’s PK parameters—such as half-life, bioavailability, or renal clearance—cannot be verified from these sources, even though they may be accurate based on external clinical data.
References
- Antisense Research and Application
- Cancer_ Principles & Practice of Oncology
- Gene Therapy_ Therapeutic Mechanisms and Strategies
- Growth Hormone Secretagogues in Clinical Practice
- Handbook of Biologically Active Peptides
- Peptide Chemistry and Drug Design
- Peptide Therapeutics_ Design and Development
- Pharmacologic Therapy of Skin Disease
- Plant Bioactive Molecules
- Principles and Practice of the Biologic Therapy of Cancer
- Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga
Continue your research
Part of our SS-31: Dosing, Forms & Administration guide.
- What is the optimal dosing regimen of SS-31 in preclinical models of cardiac and neurological injury, and how does route of administration affect bioavailability?
- Are there dose-dependent effects of SS-31 on mitochondrial function and tissue protection, and what is the therapeutic window observed in animal studies?
- Are there sex-specific differences in SS-31 response or pharmacokinetics in preclinical models?
Related topics:
- What are the long-term safety and toxicity profiles of SS-31 in animal models, and are there any reported adverse effects at therapeutic doses?
- What evidence supports SS-31's ability to accelerate tissue repair in models of myocardial infarction, and which cellular processes are enhanced?
- How does SS-31 influence endothelial regeneration and angiogenesis in ischemic injury models, and what signaling pathways are involved?